申请人:Institut Curie
公开号:EP2926815A1
公开(公告)日:2015-10-07
The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
本发明涉及一类新的式(I)头孢菌素衍生物,特别是具有 CXCR4 受体拮抗剂作用的衍生物,可作为治疗癌症,特别是治疗乳腺癌、肺癌和葡萄膜黑色素瘤的治疗剂。本发明还涉及一种药物组合物,该药物组合物包含式(I)化合物和另一种治疗癌症的抗肿瘤药物。